Vykat™ XR Improves Hyperphagia and Behavioral Symptoms in PWS
Soleno Therapeutics announced positive data from its clinical development program for VYKAT XR (diazoxide choline) extended-release tablets, a treatment...
Advanced Skin Cancer Patient in Remission After WTX-124 Trial
A patient with advanced cutaneous squamous cell carcinoma (CSCC) experienced complete tumor remission after 12 weeks in a clinical...
ORUKA Therapeutics Doses First Participants in Phase 1 Trial of Anti-IL-17A/F Antibody
Oruka Therapeutics has started dosing healthy volunteers in a Phase 1 clinical trial for ORKA-002, a novel subcutaneous monoclonal...
Lymphodepletion Improves T Cell Expansion in Lymphoma Patients
Marker Therapeutics announced preliminary findings from its Phase 1 APOLLO study, showing that lymphodepletion, a pre-conditioning regimen, improves the...
Cingulate ADHD Study: CTX-1301 Efficacy Results Announced
Cingulate Inc. announced positive efficacy results from a Phase 3 clinical trial of CTx-1301, its dexmethylphenidate-based ADHD treatment, in...
SPRINT PNS Meets Primary Endpoint in MONARCH Study
SPR announced positive results from its MONARCH study, which investigated the use of its SPRINT PNS System for treating...
Silo Pharma & Resyca Partner for PTSD Drug Study
Silo Pharma (Nasdaq: SILO) partnered with Resyca BV to conduct a drug-device study for their lead asset, SPC-15, an...
Silexion Shows Promising Preclinical Results in Cancer Studies
Silexion Therapeutics (NASDAQ: SLXN) has completed preclinical studies of its RNAi therapeutic candidate, SIL204, in colorectal, lung, and pancreatic...
Risvodetinib for Parkinson’s: End of Phase 2 FDA Meeting Details Announced
ABLi Therapeutics recently completed an End of Phase 2 meeting with the FDA to discuss results from their Parkinson’s...
Summit Max Trial Shows Highest First Pass Effect in Stroke Thrombectomy
Route 92 Medical announced positive results from its SUMMIT MAX trial of the HiPoint Reperfusion System, including the super-bore...